Arbutus Biopharma Corporation announced that after a distinguished 38-year career, the Company?s co-founder and Chief Scientific Officer, Dr. Michael Sofia, will retire effective December 31, 2024. Dr. Sofia is a globally recognized, Lasker award-winning antiviral drug discovery and development scientist.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.14 USD | -0.63% | -1.88% | +25.60% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.60% | 593M | |
+0.85% | 92.38B | |
-3.03% | 37.9B | |
-10.46% | 33.73B | |
+74.71% | 27.98B | |
-13.39% | 15.86B | |
-1.08% | 13.97B | |
-11.15% | 11.67B | |
+169.04% | 10.17B | |
-50.19% | 10.04B |
- Stock Market
- Equities
- ABUS Stock
- News Arbutus Biopharma Corporation
- Arbutus Biopharma Corporation Announces Retirement of Chief Scientific Officer, Michael J. Sofia Effective December 31, 2024